Ipsen delivers strong sales in the first quarter of 2025

16 April 2025

French drugmaker Ipsen (Euronext: IPN) today presented sales for the first quarter of 2025. The company did not release any earnings figures.

Total sales were 918.8 million euros ($1,041 million), showing growth of 11.6% at constant exchange rates (CER), or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo (elafibranor) and Bylvay (odevixibat).

“Ipsen has delivered a strong start to 2025, building further momentum in the transformation of our company,” commented David Loew, chief executive of Ipsen, adding: “We continued to execute on our strategy with strong top-line growth and pipeline progression. I am pleased to see the rapid build-up of our rare cholestatic liver disease franchise with two innovate medicines for five indications. 2025 is set to be an important year for Ipsen, with multiple launches underway and several milestones expected across our portfolio.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK